Latin American consensus on guidelines for chronic migraine treatment

Chronic migraine is a condition with significant prevalence all around the world and high socioeconomic impact, and its handling has been challenging neurologists. Developments for understanding its mechanisms and associated conditions, as well as that of new therapies, have been quick and important, a fact which has motivated the Latin American and Brazilian Headache Societies to prepare the present consensus. The treatment of chronic migraine should always be preceded by a careful diagnosis review; the detection of possible worsening factors and associated conditions; the stratification of seriousness/ impossibility to treat; and monitoring establishment, with a pain diary. The present consensus deals with pharmacological and nonpharmacological forms of treatment to be used in chronic migraine

Latin American Consensus On Guidelines For Chronic Migraine Treatment

Chronic migraine is a condition with significant prevalence all around the world and high socioeconomic impact, and its handling has been challenging neurologists. Developments for understanding its mechanisms and associated conditions, as well as that of new therapies, have been quick and important, a fact which has motivated the Latin American and Brazilian Headache Societies to prepare the present consensus. The treatment of chronic migraine should always be preceded by a careful diagnosis review; the detection of possible worsening factors and associated conditions; the stratification of seriousness/ impossibility to treat; and monitoring establishment, with a pain diary. The present consensus deals with pharmacological and nonpharmacological forms of treatment to be used in chronic migraine.717478486(2004) International Classification of Headache Disorders, 24, pp. S1-S160. , International Headache Society Classification Subcommittee 2nd edition. Cephalalgia(2011) Atlas of Headache Disorders and Resources in the World, , World Health Organization Geneva: WHO2011Stovner, L.J., Hagen, K., Jensen, R., The global burden of headache: A documentation of headache prevalence and disability worldwide (2007) Cephalalgia, 27, pp. 193-210Natoli, J.L., Manack, A., Dean, B., Global prevalence of chronic migraine: A systematic review (2010) Cephalalgia, 30, pp. 599-609Lipton, R.B., Bigal, M.E., Diamond, M., Migraine prevalence, disease burden, and the need for preventive therapy (2007) Neurology, 68, pp. 343-349. , AMPP Advisory GroupSilva Junior, A.A., Tavares, R.M., Lara, R.R., Faleiros, B.E., Gomez, R.S., Teixeira, A.L., Frequency of types of headache in the tertiary care center of the hospital das clinicas of the universidade federal de minas gerais, MG, Brazil (2012) Rev Assoc Med Bras, 58, pp. 709-713Davies, P., Medication overuse headache: A silent pandemic (2012) Pain, 153, pp. 7-8Altena, M., Katsarava, Z., Nappi, G., COMOESTAS consortium. From drug-induced headache to medication overuse headache. A short epidemiological review, with a focus on latin American countries (2009) J Headache Pain, 10, pp. 71-76Manack, A., Buse, D.C., Serrano, D., Türkei, C.C., Lipton, R.B., Rates, predictors, and consequences of remission from chronic migraine to episodic migraine (2011) Neurology, 76, pp. 711-718Buse, D.C., Manack, A., Serrano, D., Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers (2010) J Neurol Neurosurg Psychiatry, 81, pp. 428-432Stokes, M., Becker, W.J., Lipton, R.B., Cost of health care among patients with chronic and episodic migraine in canada and the USA: Results from the international burden of migraine study (IBMS) (2011) Headache, 51, pp. 1058-1077Cevoli, S., Sancisi, E., Pierangeli, G., Chronic daily headache: Risk factors and pathogenic considerations (2006) Neurol Sci, 27, pp. S168-S173Silberstein, S.D., Upton, R.B., Sliwinski, M., Classification of daily and near-daily headaches: Field trial of revised IHS criteria (1996) Neurology, 47, pp. 871-875Saper, J.R., The mixed headache syndrome: A new perspective (1982) Headache, 22, pp. 284-286Mathew, N.T., Transformed migraine (1993) Cephalalgia, 13, pp. S78-S83Olesen, J., Bousser, M.G., Diener, H.C., Headache classification committee. New appendix criteria open for a broader concept of chronic migraine (2006) Cephalalgia, 26, pp. 742-746Gl, S., Park, J.W., Shin, H.E., Differences in clinical features and disability according to the frequency of medication use in patients with chronic migraine (2012) J Clin Neurol, 8, pp. 198-203Pozo-Rosich, P., Migrana crónica: Epidemiologia e impacto (2012) Rev Neurol, 54, pp. S3-S11Goadsby, P.J., Charbit, A.R., Andreou, A.P., Neurobiology of migraine (2009) Neuroscience, 161, pp. 327-341Lipton, R.B., Tracing transformation: Chronic migraine classification, progression, and epidemiology (2009) Neurology, 72, pp. S3-S7Srikiatkhachom, A., Chronic daily headache: A scientist's perspective (2002) Headache, 42, pp. 523-537Kruit, M.C., Van Büchern, M.A., Launer, U., Migraine is associated with an increased risk of deep white matter lesions, subclinical posterior circulation infarcts and brain iron accumulation: The population-based MRI CAMERA study (2010) Cephalalgia, 30, pp. 129-136Spector, J.T., Kahn, S.R., Jones, M.R., Migraine headache and ischemic stroke risk: An updated meta-analysis (2010) Am J Med, 123, pp. 612-624Chen, Y.C., Tang, C.H., Ng, K., Comorbidity profiles of chronic migraine sufferers in a national database in Taiwan (2012) J Headache Pain, 13, pp. 311-319Yoon, G., Baggaley, S., Bacchetti, P., Clinic-based study of family history of vascular risk factors and migraine (2005) J Headache Pain, 6, pp. 412-416Bigal, M.E., Kurth, T., Santanello, N., Migraine and cardiovascular disease: A population-based study (2010) Neurology, 74, pp. 628-635Tembl, J., Lago, A., Sevilla, T., Migraine, patent foramen ovale and migraine triggers (2007) J Headache Pain, 8, pp. 07-12Garg, P., Servoss, S.J., Wu, J.C., Lack of association between migraine headache and patent foramen ovale: Results of a case-control study (2010) Circulation, 121, pp. 1406-1412Merikangas, K.R., Angst, J., Isler, H., Migraine and psychopathology. Results of the zurich cohort study of young adults (1990) Arch Gen Psychiatry, 47, pp. 849-853Teixeira, A.L., Costa, E.A., Alberto Da Silva Jr., A., Psychiatric comorbidities of chronic migraine in community and tertiary care clinic samples (2012) J Headache Pain, 13, pp. 551-555Ottman, R., Lipton, R.B., Ettinger, A.B., Comorbidities of epilepsy: Results from the epilepsy comorbidities and health (EPIC) survey (2011) Epilepsia, 52, pp. 308-315Von Brevem, M., Neuhauser, H., Epidemiological evidence for a link between vertigo and migraine (2011) J Vestib Res, 21, pp. 299-304Kister, I., Caminero, A.B., Herbert, J., Tension-type headache and migraine in multiple sclerosis (2010) Curr Pain Headache Rep, 14, pp. 441-448De Tommaso, M., Sardaro, M., Serpino, C., Fibromyalgia comorbidity in primary headaches (2009) Cephalalgia, 29, pp. 453-464Peres, M.R., Young, W.B., Kaup, A.O., Fibromyalgia is common in patients with transformed migraine (2001) Neurology, 57, pp. 1326-1328Riedl, A., Schmidtmann, M., Stengel, A., Somatic comorbidities of irritable bowel syndrome: A systematic analysis (2008) J Psychosom Res, 64, pp. 573-582Stuginski-Barbosa, J., Macedo, H.R., Bigal, M.E., Signs of temporomandibular disorders in migraine patients: A prospective, controlled study (2010) Clin J Pain, 26, pp. 418-421Goncalves, D.A., Camparis, C.M., Speciali, J.G., Temporomandibular disorders are differentially associated with headache diagnoses: A controlled study (2011) Clin J Pain, 27, pp. 611-615Katsarava, Z., Schneeweiss, S., Kurth, T., Incidence and predictors for chronicity of headache in patients with episodic migraine (2004) Neurology, 62, pp. 788-790Bigal, M.E., Serrano, D., Buse, D., Acute migraine medications in evolution from episodic to chronic migraine: A longitudinal population-based study (2008) Headache, 48, pp. 1157-1168Scher, A.I., Stewart, W.F., Ricci, J.A., Factors associated with the onset and remission of chronic daily headache in a population-based study (2003) Pain, 106, pp. 81-89Bigal, M.E., Lipton, R.B., Obesity is a risk factor for transformed migraine but not chronic tension-type headache (2006) Neurology, 67, pp. 252-257Al, S., Lipton, R.B., Stewart, W.F., Habitual snoring as a risk factor for chronic daily headache (2003) Neurology, 60, pp. 1366-1368Scher, A.I., Stewart, W.F., Lipton, R.B., Caffeine as a risk factor for chronic daily headache: A population-based study (2004) Neurology, 63, pp. 2022-2027Tietjen, G.E., Peterlin, B.L., Brandes, J.L., Depression and anxiety: Effect on the migraine-obesity relationship (2007) Headache, 47, pp. 866-875Scher, A.I., Stewart, W.F., Buse, D., Major life changes before and after the onset of chronic daily headache: A population-based study (2008) Cephalalgia, 28, pp. 868-876Lipton, R.B., Silberstein, S.D., Saper, J.R., Why headache treatment fails (2003) Neurology, 60, pp. 1064-1070Yu, S., Liu, R., Zhao, G., The prevalence and burden of primary headaches in China: A population-based door-to-door survey (2012) Headache, 52, pp. 582-591Stuginski-Barbosa, J., Dach, F., Bigal, M., Chronic pain and depression in the quality of life of women with migraine - A controlled study (2012) Headache, 52, pp. 400-408Valença, M.M., Valença, L.P.A.A., Bordini, C., Cefaleia de "dificil controle," (2003) MigrCefaleias, 6, pp. 117-120Silberstein, S.D., Dodick, D.W., Pearlman, S., Defining the pharmacologically intractable headache for clinical trials and clinical practice (2010) Headache, 50, pp. 1499-1506Recomendacöes para o tratamento da crise migranosa (2000) Arq Neuropsiquiatr, 58, pp. 371-389. , Consensu da Sociedade BrasileiraRecomendacöes para o tratamento profilático da migránea (2002) Arq Neuropsiquiatr, 60, pp. 159-169. , Consensu da Sociedade BrasileiraPascual, J., Migrana crónica: Tratamiento (2012) Rev Neurol, 54, pp. S31-S38Schwartz, T.H., Karpistikiy, W., Sohn, R.S., Intravenous valproate sodium in the treatment of daily headache (2002) Headache, 42, pp. 519-522Demirkaya, S., Vural, O., Dora, B., Efficacy of intravenous magnesium sulfate in the treatment of acute migraine attacks (2001) Headache, 41, pp. 171-177Paemeleire, K., Crevits, L., Goadsby, P.J., Practical management of medication-overuse headache (2006) Acta Neurol Belg, 106, pp. 43-51Lane, R.L., Ross, R., Intravenous chlorpromazine - Preliminary results in acute migraine (1985) Headache, 25, pp. 302-304Monzillo, P.H., Nemoto, P.H., Costa, A.R., Acute treatment of migraine in emergency room: Comparative study between dexametasone and haloperidol. Preliminary results (2004) Arq Neuropsiquiatr, 62, pp. 513-518Hill, C.H., Miner, J.R., Martel, M.L., Olanzapine versus dropendol for the treatment of primary headache in the emergency department (2008) Acad Emerg Med, 15, pp. 806-811Silberstein, S.B., Peres, M.R., Olanzapine in the treatment of refractory headache (2002) Headache, 42, pp. 515-518Mendes, P.M., Silberstein, S.D., Young, W.B., Intravenous propofol in the treatment of refractory headache (2002) Headache, 42, pp. 638-641Dusitanond, P., Young, W.B., Neuroleptics and migraine (2009) Cent Nerv Syst Agents Med Chem, 9, pp. 63-70Krymchantowski, A.V., Jevoux, C., Moreira, P.R., An open pilot study assessing the benefits of quetiapine for the prevention of migraine refractory to the combination of atenolol, nortriptyline, and flunarizine (2010) Pain Med, 11, pp. 48-52Obermann, M., Katsarava, Z., Management of medication-overuse headache (2007) Expert Rev Neurother, 7, pp. 1145-1155Pageler, L., Katsarava, Z., Diener, H.C., Prednisone vs. Placebo in withdrawal therapy following medication overuse headache (2008) Cephalalgia, 28, pp. 152-156Katsarava, Z., Holle, D., Diener, H.C., Medication overuse headache (2009) Curr Neurol Neurosci Rep, 9, pp. 115-119Zeeberg, P., Olesen, J., Jensen, R., Discontinuation of medication overuse in headache patients: Recovery of therapeutic responsiveness (2006) Cephalalgia, 26, pp. 1192-1198Rossi, R., Jensen, R., Nappi, G., A narrative review on the management of medication overuse headache: The steep road from experience to evidence (2009) J Headache Pain, 10, pp. 407-417Dodick, D.W., Türkei, C.C., DeGryse, R.E., Onabotulinumtoxma for treatment of chronic migraine: Pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program (2010) Headache, 50, pp. 921-936. , PREEMPT Chronic Migraine Study GroupDiener, H.C., Dodick, D.W., Aurora, S.K., Onabotulinumtoxin A for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial (2010) Cephalalgia, 30, pp. 804-814. , PREEMPT 2 Chronic Migraine Study GroupSilberstein, S.D., Lipton, R.B., Dodick, D.W., Efficacy and safety of topiramate for the treatment of chronic migraine: A randomized, double-blind, placebo-controlled trial (2007) Headache, 47, pp. 170-180. , TopiramateChronic Migraine Study GroupSilvestrini, M., Bartolini, M., Coccia, M., Topiramate in the treatment of chronic migraine (2003) Cephalalgia, 23, pp. 820-824Diener, H.C., Bussone, G., Van Oene, J.C., Topiramate reduces headache days in chronic migraine: A randomized, double-blind, placebo-controlled study (2007) Cephalalgia, 27, pp. 814-823. , TOPMAT-MIG-201 (TOP-CHROME) Study GroupYurekli, V.A., Akhan, G., Kutluhan, S., The effect of sodium valproate on chronic daily headache and its subgroups (2008) J Headache Pain, 9, pp. 37-41Silberstein, S.D., Neto, W., Schmitt, J., Topiramate in migraine prevention: Results of a large controlled trial (2004) Arch Neurol, 61, pp. 490-495. , MIGR-001 Study GroupBrandes, J.L., Saper, J.R., Diamond, M., Topiramate for migraine prevention: A randomized controlled trial (2004) JAMA, 291, pp. 965-973. , MIGR-002 Study GroupSilberstein, S.D., Hulihan, J., Karim, M.R., Efficacy and tolerability of topiramate 200 mg/d in the prevention of migraine with/without aura in adults: A randomized, placebo-controlled, double-blind, 12-week pilot study (2006) Clin Ther, 28, pp. 1002-1011Silberstein, S., Lipton, R., Dodick, D., Topiramate treatment of chronic migraine: A randomized, placebo-controlled trial of quality of life and other efficacy measures (2009) Headache, 49, pp. 1153-1162Hering, R., Kuntzky, A., Sodium valproate in the prophylactic treatment of migraine: A double-blind study versus placebo (1992) Cephalalgia, 12, pp. 81-84Silberstein, S.D., Collins, S.D., Long-term safety of depakote in headache prophylaxis study group (1999) Headache, 39, pp. 633-643. , Safety of divalproex sodium in migraine prophylaxis: an open-label, long-term studyFreitag, F.G., Collins, S.D., Carlson, H.A., Depakote, E.R., A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis (2002) Neurology, 58, pp. 1652-1659. , Migraine Study GroupRowe, A., Lachinski, R., Rizelio, V., Hospital management of intractable headaches. The institute de neurologia de curitiba approach (2011) Head Med, 2, pp. 194-199Lionetto, L., Negro, A., Palmisani, S., Emerging treatment for chronic migraine and refractory chronic migraine (2012) Expert Opin Emerg Drugs, 17, pp. 393-406Aurora, S.K., Dodick, D.W., Türkei, C.C., Onabotulinumtox in A for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial (2010) Cephalalgia, 30, pp. 793-803. , PREEMPT 1 Chronic Migraine Study GroupDiener, H.C., Dodick, D.W., Aurora, S.K., Onabotulinumtox in A for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial (2010) Cephalalgia, 30, pp. 804-814. , PREEMPT 2 Chronic Migraine Study GroupDiener, H.C., Detoxification for medication overuse headache is not necessary (2012) Cephalalgia, 32, pp. 423-427Aurora, S., Letter to the editor (2011) Cephalalgia, 31, pp. 378-379Cutrer, F.M., Mathew, P., Garza, I., Cutaneous allodynia as a prognostic factor in the treatment of migraine with botulinum toxin (abstract n. PO-69) (2010) 52nd Annual Service Meeting of the American Headache Society Los Angeles;Frampton, J.E., Onabotulinumtox in A (BOTOX*): A review of its use in the prophylaxis of headaches in adults with chronic migraine (2012) Drugs, 72, pp. 825-845Mathew, N.T., Jaffri, S.F., Adouble-blind comparison of onabotulinumtox in A (BOTOX) and topiramate (T0PAMAX) for the prophylactic treatment of chronic migraine: A pilot study (2009) Headache, 49, pp. 1466-1478Yang, C.P., Chang, M.H., Liu, P.E., Acupuncture versus topiramate in chronic migraine prophylaxis: A randomized clinical trial (2011) Cephalalgia, 31, pp. 1510-1521Rossi, R., Di Lorenzo, G., Malpezzi, M.G., Prevalence, pattern and predictors of use of complementary and alternative medicine (CAM) in migraine patients attending a headache clinic in Italy (2005) Cephalalgia, 25, pp. 493-506Gaul, C., Eismann, R., Schmidt, T., Use of complementary and alternative medicine in patients suffering from primary headache disorders (2009) Cephalalgia, 29, pp. 1069-1078Wells, R.E., Bertisch, S.M., Buettner, C., Complementary and alternative medicine use among adults with migraines/severe headaches (2011) Headache, 51, pp. 1087-1097Kristoffersen, E.S., Grande, R.B., Aaseth, K., Management of primary chronic headache in the general population: The akershus study of chronic headache (2012) J Headache Pain, 13, pp. 113-12

The Reference Site Collaborative Network of the European Innovation Partnership on Active and Healthy Ageing.

International audienc

The reference site collaborative network of the european innovation partnership on active and healthy ageing

Seventy four Reference Sites of the European Innovation Partnership on Active and Healthy Ageing (EIP on AHA) have been recognised by the European Commission in 2016 for their commitment to excellence in investing and scaling up innovative solutions for active and healthy ageing. The Reference Site Collaborative Network (RSCN) brings together the EIP on AHA Reference Sites awarded by the European Commission, and Candidate Reference Sites into a single forum. The overarching goals are to promote cooperation, share and transfer good practice and solutions in the development and scaling up of health and care strategies, policies and service delivery models, while at the same time supporting the action groups in their work. The RSCN aspires to be recognized by the EU Commission as the principal forum and authority representing all EIP on AHA Reference Sites. The RSCN will contribute to achieve the goals of the EIP on AHA by improving health and care outcomes for citizens across Europe, and the development of sustainable economic growth and the creation of jobs

The Reference Site Collaborative Network of the European Innovation Partnership on Active and Healthy Ageing.

International audienceSeventy four Reference Sites of the European Innovation Partnership on Active and Healthy Ageing (EIP on AHA) have been recognised by the European Commission in 2016 for their commitment to excellence in investing and scaling up innovative solutions for active and healthy ageing. The Reference Site Collaborative Network (RSCN) brings together the EIP on AHA Reference Sites awarded by the European Commission, and Candidate Reference Sites into a single forum. The overarching goals are to promote cooperation, share and transfer good practice and solutions in the development and scaling up of health and care strategies, policies and service delivery models, while at the same time supporting the action groups in their work. The RSCN aspires to be recognized by the EU Commission as the principal forum and authority representing all EIP on AHA Reference Sites. The RSCN will contribute to achieve the goals of the EIP on AHA by improving health and care outcomes for citizens across Europe, and the development of sustainable economic growth and the creation of jobs